Preventing and treating influenza

Stephen G. Baum, Jeanne Carey

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

The keystone of influenza prevention is still vaccination. The 2 available types of influenza vaccine-the inactivated vaccine, which is administered intramuscularly, and the attenuated vaccine, which is delivered via nasal spray-have efficacy rates of 70% to 80%. Unfortunately, only about 65% of persons who should receive the influenza vaccine are, in fact, vaccinated. The neuraminidase inhibitors oseltamivir and zanamivir are 70% to 90% effective in preventing influenza. These antivirals also are effective in reducing the severity of influenza symptoms and the duration of illness when administered within 48 hours of the onset of clinical disease. Some patients have difficulty in self-administering zanamivir because the inhalation process is fairly complicated. Because of the resistance pattern observed in 2005, amantadine and rimantadine are not currently recommended for prophylaxis or therapy.

Original languageEnglish (US)
Pages (from-to)21-29
Number of pages9
JournalJournal of Respiratory Diseases
Volume28
Issue number1
StatePublished - Jan 1 2007

Keywords

  • Antiviral therapy
  • Influenza
  • Vaccines

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Preventing and treating influenza'. Together they form a unique fingerprint.

  • Cite this